AKARI THERAPEUTICS PLC-ADR (AKTX)

US00972G2075 - ADR

1.865  +0 (+0.27%)

News Image
10 days ago - Halper Sadeh LLP

SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates VIVK, MINM, SDPI, AKTX

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

News Image
13 days ago - Kuehn Law, PLLC

Kuehn Law Encourages VIVK, MINM, SDPI, and AKTX Investors to Contact Law Firm

/PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law...

News Image
23 days ago - Halper Sadeh LLP

SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates AKTX, HES, TGAN, NS

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

News Image
23 days ago - Akari Therapeutics Plc

Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline That Features a Novel Antibody Drug Conjugate (ADC) Toolkit

BOSTON and PLEASANTON, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing...

News Image
3 months ago - Seeking Alpha

Akari Therapeutics announces $2M private placement financing (NASDAQ:AKTX)

Akari Therapeutics closes private placement financing with existing investors, resulting in gross proceeds of $2 million.

News Image
3 months ago - Akari Therapeutics Plc

Akari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement Financing

BOSTON and LONDON, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced...

News Image
4 months ago - Akari Therapeutics Plc

Akari Therapeutics to Present at Biotech Showcase 2024

NEW YORK and BOSTON, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced...

News Image
4 months ago - Akari Therapeutics Plc

Akari Therapeutics Appoints Experienced Life Sciences Entrepreneur Samir R. Patel, M.D. to Board of Directors

NEW YORK and BOSTON, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced...

News Image
4 months ago - Akari Therapeutics Plc

Akari Therapeutics Presents Poster on Progress in Pre-Clinical Development of Long-Acting PAS-Nomacopan as a Potential Treatment for Geographic Atrophy at the 4th Annual Dry AMD Therapeutic Development Conference

Positive pre-clinical results, including an advanced high yielding manufacturing process, support the anticipated submission of an IND in 2024 to begin...

News Image
5 months ago - Seeking Alpha

Akari Therapeutics files to sell 1.29B shares for holders (NASDAQ:AKTX)

Read about Akari Therapeutics' recent filing of a prospectus for the resale of 1.29B ordinary shares by selling shareholders. Not an offer.

News Image
6 months ago - Akari Therapeutics Plc

Akari Therapeutics Reports First Half 2023 Financial Results and Highlights

Akari’s priority pipeline programs remain on track to begin enrollment in the registrational nomacopan Phase 3 clinical trials in pediatric and adult...

News Image
6 months ago - Akari Therapeutics Plc

Akari Therapeutics to Present at Emerging Growth Conference

BOSTON and LONDON, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced...

News Image
6 months ago - Akari Therapeutics Plc

Akari Therapeutics to Host Key Opinion Leader Webinar on Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA) and the Potential of Nomacopan to Address Significant Unmet Needs

Event on October 19, 2023 will feature Sonata Jodele, MD and Professor Rob Wynn BOSTON and LONDON, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Akari...

News Image
7 months ago - Akari Therapeutics Plc

Akari Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

NEW YORK and LONDON, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced...

News Image
7 months ago - Akari Therapeutics Plc

Akari Therapeutics Announces Establishment of Boston U.S. Headquarters Office to Support Expanding Operations and Start of Registrational Phase 3 Clinical Trials

NEW YORK and LONDON, Aug. 18, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced...

News Image
7 months ago - InvestorPlace

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

It's time for another dive into the biggest pre-market stock movers this morning as we check out the latest news on Thursday!

News Image
8 months ago - Seeking Alpha

Akari Therapeutics announces ADS ratio change (NASDAQ:AKTX)

Akari Therapeutics (AKTX) said on Tuesday that it plans to change the ratio of its American Depositary Shares to ordinary shares from one ADS representing one hundred ordinary shares to...

News Image
8 months ago - Akari Therapeutics Plc

Akari Therapeutics, Plc Announces ADS Ratio Change

NEW YORK and LONDON, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced...

News Image
8 months ago - Akari Therapeutics Plc

Akari Therapeutics Appoints Experienced Life Sciences Executive Wendy DiCicco as Interim Chief Financial Officer

NEW YORK and LONDON, July 19, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced...

News Image
9 months ago - Akari Therapeutics Plc

Akari Therapeutics Provides Update on Development of Long-Acting PAS-Nomacopan for Treatment of Geographic Atrophy

Akari has completed evaluation of long-acting PAS-nomacopan candidates and selected a single drug candidate to move forward into clinical trials for...

News Image
9 months ago - Akari Therapeutics Plc

Akari Therapeutics Appoints Industry Veteran Wa’el Hashad to Board of Directors

NEW YORK and LONDON, July 05, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced...

News Image
11 months ago - Akari Therapeutics Plc

Akari Therapeutics to Participate in A.G.P.’s Virtual Healthcare Conference

NEW YORK and LONDON, May 16, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced...

News Image
a year ago - Akari Therapeutics Plc

Akari Therapeutics Reports Full-Year 2022 Financial Results and Highlights

Development of lead asset nomacopan, a novel dual-mechanism inhibitor of complement C5 and leukotriene B4 (LTB4), is focused on two priority pipeline...

News Image
a year ago - Akari Therapeutics Plc

Akari Therapeutics Granted 180-Day Extension by Nasdaq to Meet Minimum Bid Price Requirement

NEW YORK and LONDON, April 25, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced...

News Image
a year ago - Akari Therapeutics Plc

Akari Therapeutics to Host Key Opinion Leader Webinar on Geographic Atrophy and the Potential of Long-Acting PAS-Nomacopan to Address Significant Unmet Needs

Event on May 22nd will feature Elias Reichel, M.D., Professor, Department of Ophthalmology, Tufts University School of Medicine NEW YORK and LONDON, April...

News Image
a year ago - Akari Therapeutics Plc

Akari Therapeutics to Attend ARVO 2023, the Annual Meeting of The Association for Research in Vision and Ophthalmology

NEW YORK and LONDON, April 11, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced...

News Image
a year ago - Akari Therapeutics Plc

Akari Therapeutics Announces a Case Study from the Phase 3 Part A Clinical Trial of Nomacopan in Pediatric HSCT-TMA Will Be Presented at The European Society for Blood and Marrow Transplantation (EBMT) 49th Annual Meeting

NEW YORK and LONDON, April 03, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced...

News Image
a year ago - Akari Therapeutics Plc

Akari Therapeutics, Plc Announces $4 Million Registered Direct Offering

Offering includes 100% participation by Akari’s Board of Directors, including Akari President and CEO Rachelle JacquesOffering includes accredited...